EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSBGRG00000013228
Gene Symbol: CACNA1B
1 Cross references
286 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSBGRG00000018838
Gene Symbol: CACNA1D
1 Cross references
280 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSBGRG00000012423
Gene Symbol: CACNA1E
1 Cross references
295 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSBGRG00000021471
Gene Symbol: CACNA1F
1 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSBGRG00000007753
Gene Symbol: CACNA1G
1 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSBGRG00000026596
Gene Symbol: CACNA1H
1 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSBGRG00000003629
Gene Symbol: CACNA1I
1 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSBGRG00000024684
Gene Symbol: CACNA1S
1 Cross references
266 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSBGRG00000023046
Gene Symbol: CNR1
1 Cross references
207 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSBGRG00000005295
Gene Symbol: CNR2
1 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 1

Ensembl ID : ENSBGRG00000014309
Gene Symbol: CA1
1 Cross references
275 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSBGRG00000026023
Gene Symbol: CA12
1 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).